At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,357 enrolled
Drug / intervention
CVnCoV Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)
In Brief
A Phase 3 clinical trial evaluating CVnCoV Vaccine and Placebo for Coronavirus and 3 related conditions. Completed, enrolled 2,357 participants across 1 site.
Detailed Summary
This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
CountriesGermany
CollaboratorsGerman Federal Ministry of Education and Research
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedDec 19, 2020
Enrollment StartDec 23, 2020
Primary CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.5 years ago
Interventions
CVnCoV Vaccinebiological
Intramuscular injection
Placebodrug
Intramuscular injection